[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Maezawa T, Yonese J, Tsukamoto T, Ishii N, Fukui I: [Combination chemotherapy with ifosfamide, 5-fuluorouracil, etoposide and cisplatin for advanced urothelial cancer: the treatment results and significance of tumor marker evaluation in response assessment of chemotherapy]. Nihon Hinyokika Gakkai Zasshi; 2002 Nov;93(7):727-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combination chemotherapy with ifosfamide, 5-fuluorouracil, etoposide and cisplatin for advanced urothelial cancer: the treatment results and significance of tumor marker evaluation in response assessment of chemotherapy].
  • PURPOSE: We investigated treatment results of IFEPchemotherapy in patients with advanced urothelial cancer (N2-3, M1) and the usefulness of measuring serum CEA, CA19-9 and SCC to evaluate the treatment response of chemotherapy.
  • PATIENTS AND METHODS: From March 1994 to May 2000, we treated 41 patients with IFEP therapy consisting of ifosfamide (2 g/m2), 5-fluorouracil (750 mg/m2), etoposide (100 mg/m2) and cisplatin (20 mg/m2), all of which were given daily for 3 consecutive days every 3 weeks.
  • Before initiating the chemotherapy, serum CEA, CA19-9 and SCC were measured.
  • RESULTS: The response rate of the chemotherapy was 53.7% (CR + PR), with a median survival period being 10.8 months and a median duration of response for the 22 responders being 7.5 months.
  • Response rates of primary tumors and metastatic lesions to the lymph node, bone, lung and liver were in 54% and 57%, 56%, 50% and 40%, respectively.
  • Bone marrow toxicity was significant with 1 drug-related death.
  • Before chemotherapy, tumor marker was elevated in 19 patients: CEA in 7, CA19-9 in 13 and SCC in 10.
  • Serum levels of the tumor markers were related neither to the primary and metastatic tumor sites nor to patient's survival time.
  • However, decline of serum tumor markers after chemotherapy was well related to response of the tumor assessed by imaging studies.
  • CONCLUSION: IFEP chemotherapy appears to be active in the treatment of advanced urothelial tumor and serial measurement of serum CEA, CA19-9 and SCC may be useful in judgement of tumor response to the chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Carcinoma, Transitional Cell / drug therapy. Serpins. Urologic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antigens, Neoplasm / blood. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Cisplatin / administration & dosage. Etoposide / administration & dosage. Evaluation Studies as Topic. Female. Fluorouracil / administration & dosage. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / drug therapy

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12494517.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Serpins; 0 / squamous cell carcinoma-related antigen; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


2. Tamura K, Inoue K, Fukata S, Kamada M, Shuin T: [Small cell carcinoma of the urinary bladder with synchronous esophageal cancer and incidental lung cancer: a case report]. Hinyokika Kiyo; 2001 Apr;47(4):273-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Small cell carcinoma of the urinary bladder with synchronous esophageal cancer and incidental lung cancer: a case report].
  • We present a case of triple primary cancers occurring synchronously in the urinary bladder, esophagus, and incidentally in the lung.
  • Cystoscopy, computed tomography (CT) and magnetic resonance imaging (MRI) revealed a non-papillary broad-based bladder tumor.
  • Histological diagnosis was transitional cell carcinoma of the urinary bladder and he underwent one course of neoadjuvant chemotherapy (M-VAC) with the preoperative diagnosis of T3bN0M0.
  • After one course of chemotherapy, chest CT, lymph node biopsy and esophagoscopy revealed squamous cell carcinoma of the esophagus.
  • He first underwent radiochemotherapy (total 70 Gy, CDDP 5 mg x 41, 5-FU 250 mg x 24) for esophageal cancer and achieved complete remission.
  • Then, he underwent radiotherapy for a total of 60 Gy for bladder cancer.
  • The autopsy proved that he died from multiple metastases of small cell carcinoma of the urinary bladder and incidentally squamous cell carcinoma of the lung was identified.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / pathology. Esophageal Neoplasms / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary. Urinary Bladder Neoplasms / pathology


3. Hisamatsu H, Yamashita S: [A case of metastatic lung cancer with cavitation due to urothelial carcinoma]. Hinyokika Kiyo; 2010 May;56(5):269-72
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metastatic lung cancer with cavitation due to urothelial carcinoma].
  • We report a rare case of lung cancer with cavitation that was caused by metastasis of urothelial carcinoma.
  • Computed tomography revealed a left ureter tumor, which was removed by left nephroureterectomy in October 2003.
  • Subsequently, transurethral resection was performed several times for bladder tumor.
  • The pathological diagnosis in February 2005 was pT2.
  • Cisplatin-based intra-arterial chemotherapy was performed because it was not possible to perform a cystectomy due to the poor performance status.
  • In March 2006, computed tomography of the chest revealed a mass shadow with a cavity in the left lower lung field.
  • This was diagnosed as primary or metastatic lung cancer and was treated by left lower lobectomy in November 2006.
  • On the basis of the pathological findings, we diagnosed the mass as metastatic tumor secondary to the urothelial carcinoma.
  • Despite general chemotherapy, the patient's condition deteriorated, and the patient died 1 year later.
  • [MeSH-major] Carcinoma, Transitional Cell / radiography. Carcinoma, Transitional Cell / secondary. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Ureteral Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Female. Humans. Nephrectomy. Sigmoid Neoplasms / pathology. Tomography, X-Ray Computed. Ureter / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20519925.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Osaka K, Kobayashi M, Takano T, Tsuchiya F, Iwasaki A, Ishizuka E, Nagashima Y: [Two cases of granulocyte-colony stimulating factor-producing infiltrating urothelial carcinoma of the kidney]. Hinyokika Kiyo; 2009 Apr;55(4):223-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of granulocyte-colony stimulating factor-producing infiltrating urothelial carcinoma of the kidney].
  • We report two cases of granulocyte-colony stimulating factor (G-CSF) producing infiltrating urothelial carcinoma of the kidney.
  • Under the diagnosis of pyonephrosis or renal tumor, we performed right radical nephrectomy.
  • The patient died of lung and liver metastases 6 months postoperatively despite of adjuvant chemotherapy.
  • The patient died of liver and lung metastases 4 months postoperatively.
  • The pathological and histochemical findings of these two cases were G-CSF producing infiltrating transitional cell carcinoma of the kidney.
  • To our knowledge, they are the first two cases of G-CSF producing infiltrating urothelial carcinoma of the kidney in Japanese literature.
  • [MeSH-major] Carcinoma, Transitional Cell / metabolism. Granulocyte Colony-Stimulating Factor / biosynthesis. Kidney Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19462829.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


5. Masue T, Taniguchi M, Takeuchi T, Sakai S: [A case report of sarcomatoid carcinoma of the bladder with metastasis to small intestine]. Nihon Hinyokika Gakkai Zasshi; 2005 Sep;96(6):640-3
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of sarcomatoid carcinoma of the bladder with metastasis to small intestine].
  • Under the clinical diagnosis of TCC G2 > G3, T3bNOM0, radical cystectomy with orthotopic bladder substitution was performed.
  • Pathological diagnosis was TCC G3 with sarcomatoid carcinoma, pT2pR0pL1 pVlpN0.
  • Adjuvant chemotherapy was not performed because of his transient poor conditions.
  • Lung metastasis was observed 6 months postoperatively.
  • Despite of M-VAC therapy and radiation therapy, additional metastases to brain and liver were observed.
  • One month later, partial ileectomy specimen for occlusive ileum revealed the same histologic findings, TCC G3 with sarcomatoid carcinoma.
  • To our knowledge, this is the first case of sarcomatoid carcinoma of the bladder with metastasis to small intestine, although 6 cases of transitional cell carcinoma of the bladder with metastasis to small intestine has been reported in Japan.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Carcinosarcoma / secondary. Ileal Neoplasms / secondary. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16218407.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 11
  •  go-up   go-down


6. Otrock ZK, Mahfouz RA, Salem ZM: Four primary tumors of lung, bladder, prostate, and breast in a male patient. South Med J; 2005 Sep;98(9):946-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four primary tumors of lung, bladder, prostate, and breast in a male patient.
  • Immunohistochemical stains showed tumor cell nuclei to be negative for p53 over-expression.
  • The tumors included an adenosquamous cell carcinoma of the lung, transitional cell carcinoma of the urinary bladder, and adenocarcinomas of the prostate and the breast.
  • [MeSH-major] Breast Neoplasms / complications. Carcinoma / complications. Lung Neoplasms / complications. Prostatic Neoplasms / complications. Urologic Neoplasms / complications
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystectomy. Fatal Outcome. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Mastectomy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Radiotherapy, Adjuvant. Shock, Septic / complications. Spinal Neoplasms / complications. Spinal Neoplasms / diagnosis. Spinal Neoplasms / secondary. Urinary Diversion

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217994.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Davies BJ, Bastacky S, Chung SY: Large cerebellar lesion as original manifestation of transitional cell carcinoma of the bladder. Urology; 2003 Oct;62(4):749
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large cerebellar lesion as original manifestation of transitional cell carcinoma of the bladder.
  • Patients with transitional cell carcinoma of the bladder classically present with irritative voiding symptoms or painless hematuria.
  • Common sites of vascular metastases include the liver (38%), lung (36%), bone (27%), adrenal glands (21%), and intestine (13%).
  • Vascular metastasis to the brain, without a prior history of chemotherapy, is extremely rare.
  • To our knowledge, this is the first report of a patient with bladder transitional cell carcinoma whose original presentation was from a symptomatic, metastatic, cerebellar lesion.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Cerebellar Neoplasms / secondary. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebellar Ataxia / etiology. Cisplatin / administration & dosage. Combined Modality Therapy. Craniotomy. Cystectomy. Doxorubicin / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Radiosurgery. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14550465.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


8. Morgan K, Srinivas S, Freiha F: Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testis. Urology; 2004 Oct;64(4):808-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testis.
  • Primary tumors known to metastasize to the testis, in order of decreasing frequency, are prostate, lung, gastrointestinal tract, melanoma, and kidney tumors.
  • We report a rare, and probably the first, case of solitary and synchronous metastatic transitional cell carcinoma of the bladder to the testis, discovered on the preoperative workup.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Deoxycytidine / analogs & derivatives. Testicular Neoplasms / secondary. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cystectomy. Cystitis / complications. Cystitis / diagnosis. Hematuria / etiology. Humans. Incidental Findings. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Neoplasms, Second Primary. Orchiectomy. Positron-Emission Tomography. Prostatectomy. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy. Prostatic Neoplasms / secondary. Radiation Injuries / complications. Radiation Injuries / diagnosis. Transurethral Resection of Prostate. Urinary Diversion

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15491734.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Antoine M: [Contribution of immunohistochemistry to the management of lung cancer: from morphology to diagnosis and treatment]. Rev Pneumol Clin; 2007 Jun;63(3):183-92
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Contribution of immunohistochemistry to the management of lung cancer: from morphology to diagnosis and treatment].
  • [Transliterated title] Qu'apporte l'immunohistochimie à la prise en charge du cancer bronchique? De la morphologie au diagnostic et au traitement.
  • We detail here the contribution of IHC to the classification of lung cancer: small-cell lung cancer and other neuroendocrine tumors, basaloid carcinoma, large-cell carcinoma.
  • The distinction is less clear for large-cell carcinoma or squamous-cell carcinoma, or for tumors with a pleural or mediastinal presentation.
  • By demonstrating the presence of carcinomatous cells within the neighboring structures (pleura) or lymph nodes, IHC contributes to lung cancer staging, particularly when there are few of these elements morphologically difficult to distinguish.
  • Finally, IHC contributes to prognosis (proliferation markers, differentiation markers) or prediction of therapeutic response (chemotherapy or targeted therapies).
  • IHC studies may also be requested in a forensic setting, for example to demonstrate that the lung cancer observed in a patient exposed to asbestosis is primary.
  • Other morphological techniques such as hybridization in situ or molecular biology techniques will further complete the histological diagnosis in the future.
  • [MeSH-major] Immunohistochemistry. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Carcinoma, Large Cell / pathology. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / pathology. Chorionic Gonadotropin, beta Subunit, Human / analysis. Forecasting. Humans. Lymph Nodes / pathology. Lymphoma / pathology. Mediastinal Neoplasms / pathology. Melanoma / pathology. Neoplasm Staging. Neuroendocrine Tumors / pathology. Pleural Neoplasms / pathology. Prognosis. Sarcoma / pathology. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17675942.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  •  go-up   go-down


10. Shahab N: Extrapulmonary small cell carcinoma of the bladder. Semin Oncol; 2007 Feb;34(1):15-21
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extrapulmonary small cell carcinoma of the bladder.
  • Among the many sites for primary small cell cancer is the genitourinary system.
  • Small cell carcinoma accounts for less than 1% of all bladder tumors.
  • Definitive predisposing factors are unknown; however, small cell carcinoma of the bladder has been associated with cigarette smoking, long-standing cystitis, bladder calculus, and augmented cystoplasty.
  • Contrary to the early theory of derivation from Kulchitsky cells, it is now believed that small cell carcinoma of the bladder originates from the totipotent stem cells present in the submucosa of the bladder wall.
  • A number of chromosomal aberrations have been reported in small cell cancer of the bladder.
  • There are no specific clinical features that differentiate these patients from transitional cell carcinoma of the bladder; however, some patients may have associated paraneoplastic conditions.
  • Diagnosis is established by cystoscopic-assisted biopsy.
  • Like small cell carcinoma of the lung, small cell carcinoma of the bladder has a propensity for early metastases.
  • There is no standard therapy for small cell carcinoma of the bladder and the prognosis is poor; however, patients treated with cisplatin-based chemotherapy regimens seem to have a better prognosis.
  • [MeSH-major] Carcinoma, Small Cell. Urinary Bladder Neoplasms
  • [MeSH-minor] Combined Modality Therapy. Cystectomy. Humans. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17270661.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 91
  •  go-up   go-down


11. Ramalingam P, Middleton LP, Tamboli P, Troncoso P, Silva EG, Ayala AG: Invasive micropapillary carcinoma of the breast metastatic to the urinary bladder and endometrium: diagnostic pitfalls and review of the literature of tumors with micropapillary features. Ann Diagn Pathol; 2003 Apr;7(2):112-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive micropapillary carcinoma of the breast metastatic to the urinary bladder and endometrium: diagnostic pitfalls and review of the literature of tumors with micropapillary features.
  • Carcinomas with micropapillary features have been described in the breast, urinary bladder, lung, and ovary.
  • The metastatic carcinoma can consist exclusively of the micropapillary component, which may elicit an erroneous diagnosis if located in the bladder or lung, as in the patient presented herein.
  • We present a case of a 59-year-old woman with a history of bilateral breast carcinoma status post-bilateral mastectomy, chemotherapy, and tamoxifen therapy.
  • A biopsy of the endometrium revealed a poorly differentiated carcinoma.
  • Urinary bladder biopsies showed a carcinoma with micropapillary features diagnosed as micropapillary transitional cell carcinoma.
  • Anderson Cancer Center (Houston, TX) for further treatment recommendations.
  • The mastectomy specimen showed an invasive ductal carcinoma with a significant micropapillary component.
  • In view of the morphologic and immunohistochemical profile, the carcinoma in the endometrium and urinary bladder were interpreted as metastatic lesions from the breast primary.
  • Carcinomas with a micropapillary component are morphologically identical in the breast, urinary bladder, and lung.
  • However, micropapillary serous carcinoma has a different appearance more akin to borderline tumors of the ovary.
  • Immunohistochemical stains are useful in distinguishing these lesions in that thyroid transcription factor-1 positivity suggests a lung primary, CK7 and estrogen receptor suggest a breast primary, and both CK7 and CK20 positivity suggest a urinary bladder primary.
  • It is important to exclude metastatic carcinomas with micropapillary features before making a definite diagnosis of a primary tumor.
  • This article discusses the differential diagnosis of carcinomas with micropapillary features in different organs.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Carcinoma, Papillary / secondary. Endometrial Neoplasms / secondary. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Carcinoma, Transitional Cell / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-7. Keratins / metabolism. Lung Neoplasms / metabolism. Middle Aged. Receptors, Estrogen / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Elsevier Inc. All rights reserved.
  • (PMID = 12715337.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / Receptors, Estrogen; 68238-35-7 / Keratins
  •  go-up   go-down


12. Maruyama T, Kubo M, Shinchou M, Hashimoto T, Mitsui Y, Ueda Y, Suzuki T, Higuchi Y, Qui J, Kondoh N, Nojima M, Yamamoto S, Shima H, Hirota S: [Case with renal pelvic carcinoma with giant hydronephrosis]. Hinyokika Kiyo; 2008 Nov;54(11):727-31
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case with renal pelvic carcinoma with giant hydronephrosis].
  • Computed tomography (CT) revealed left giant hydronephrosis containing high-density fluid which was suspected of hemorrhage in the renal pelvis.
  • Systemic examination by CT and magnetic resonance imaging (MRI) showed renal pelvic tumors in the left kidney as well as multiple metastatic lesions in the lung, liver and bone.
  • Pathological examination of the left renal pelvic tumors obtained by biopsy showed high-grade urothelial carcinoma.
  • Although systemic and intra-arterial chemotherapy showed partial response in the metastatic lesions, he died of cancer 1 year and 3 months after the first diagnosis.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Hydronephrosis / etiology. Kidney Neoplasms / diagnosis. Kidney Pelvis
  • [MeSH-minor] Bone Neoplasms / secondary. Diagnostic Imaging. Fatal Outcome. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068727.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 22
  •  go-up   go-down


13. Antonelli A, Simeone C, Ferrari V, Tardanico R, Cunico SC: Durable and complete remission of a metastatic bladder sarcomatoid carcinoma with chemotherapic and surgical treatments. Arch Ital Urol Androl; 2006 Jun;78(2):67-70
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable and complete remission of a metastatic bladder sarcomatoid carcinoma with chemotherapic and surgical treatments.
  • The sarcomatoid carcinoma of the urinary bladder is a rare variant of transitional carcinomas with an extremely aggressive clinical course and dismal prognosis regardless therapies.
  • The diagnosis of a bladder sarcomatoid carcinoma involving perivesical tissues with limphnodal, hepatic and lung metastasis was done in a 34-years old male.
  • The disease underwent complete remission after neoadjuvant chemotherapy with adriblastine and ifosfamide, radical surgery and adjuvant chemotherapy with the same drugs, as confirmed by CT, vesical biopsies during chemotherapy and by the findings detected on the surgical specimen.
  • The sarcomatoid bladder carcinoma is a rare variant of transitional carcinoma (0.31%), usually diagnosed in the late decades of life, with a survival time of a few months for metastatic patients regardless of any adopted therapies.
  • Due to the rarity of the disease and the consequent unfeasibility of randomized studies, in our opinion these results, even if obtained in a single case, suggest a viable therapeutic option.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929607.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


14. Gualberto A, Dolled-Filhart M, Gustavson M, Christiansen J, Wang YF, Hixon ML, Reynolds J, McDonald S, Ang A, Rimm DL, Langer CJ, Blakely J, Garland L, Paz-Ares LG, Karp DD, Lee AV: Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res; 2010 Sep 15;16(18):4654-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition.
  • PURPOSE: This study aimed to identify molecular determinants of sensitivity of non-small cell lung cancer (NSCLC) to anti-insulin-like growth factor receptor (IGF-IR) therapy.
  • EXPERIMENTAL DESIGN: A total of 216 tumor samples were investigated, of which 165 consisted of retrospective analyses of banked tissue and an additional 51 were from patients enrolled in a phase II study of figitumumab, a monoclonal antibody against IGF-IR, in stage IIIb/IV NSCLC.
  • RESULTS: IGF-IR was differentially expressed across histologic subtypes (P = 0.04), with highest levels observed in squamous cell tumors.
  • Elevated IGF-IR expression was also observed in a small number of squamous cell tumors responding to chemotherapy combined with figitumumab (P = 0.008).
  • Principal component analysis and unsupervised Bayesian clustering identified three NSCLC subsets that resembled the steps of the epithelial to mesenchymal transition: E-cadherin high/IRS-1 low (epithelial-like), E-cadherin intermediate/IRS-1 high (transitional), and E-cadherin low/IRS-1 low (mesenchymal-like).
  • Several markers of the IGF-IR pathway were overexpressed in the transitional subset.
  • Furthermore, a higher response rate to the combination of chemotherapy and figitumumab was observed in transitional tumors (71%) compared with those in the mesenchymal-like subset (32%; P = 0.03).
  • Only one epithelial-like tumor was identified in the phase II study, suggesting that advanced NSCLC has undergone significant dedifferentiation at diagnosis.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Appl Immunohistochem Mol Morphol. 2009 Jul;17(4):329-37 [19318915.001]
  • [Cites] Cancer Lett. 2009 Sep 8;282(1):14-24 [19345478.001]
  • [Cites] Clin Lung Cancer. 2009 Jul;10(4):281-9 [19632948.001]
  • [Cites] Mol Cancer Ther. 2009 Aug;8(8):2110-21 [19671761.001]
  • [Cites] Oncogene. 2009 Aug 27;28(34):3009-21 [19581933.001]
  • [Cites] Arch Pathol Lab Med. 2009 Sep;133(9):1413-9 [19722747.001]
  • [Cites] PLoS One. 2009;4(10):e7273 [19806209.001]
  • [Cites] Endocr Rev. 2009 Oct;30(6):586-623 [19752219.001]
  • [Cites] J Thorac Oncol. 2009 Nov;4(11):1397-403 [19745765.001]
  • [Cites] Ann Oncol. 2010 Mar;21(3):562-7 [19767315.001]
  • [Cites] J Clin Oncol. 2010 May 1;28(13):2174-80 [20351332.001]
  • [Cites] J Clin Oncol. 2009 May 20;27(15):2516-22 [19380445.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12103-8 [11035789.001]
  • [Cites] Oncogene. 2001 Aug 16;20(36):4942-50 [11526479.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2417-28 [12011119.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1323-7 [12389040.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6035-8 [12414625.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1413-8 [12433720.001]
  • [Cites] Int J Cancer. 1994 Mar 15;56(6):858-66 [7509779.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):2063-73 [15756033.001]
  • [Cites] Ann Oncol. 2006 Jul;17(7):1120-7 [16600976.001]
  • [Cites] Mol Cell Biol. 2007 Apr;27(8):3165-75 [17296734.001]
  • [Cites] Int J Cancer. 2008 Feb 1;122(3):572-82 [17955485.001]
  • [Cites] Breast Cancer Res Treat. 2008 Sep;111(1):79-91 [17902048.001]
  • [Cites] Nat Rev Cancer. 2008 Dec;8(12):915-28 [19029956.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):415-22 [19030971.001]
  • [Cites] Cancer Res. 2009 Jan 1;69(1):161-70 [19117999.001]
  • [Cites] Clin Cancer Res. 2009 Jan 1;15(1):226-37 [19118050.001]
  • [Cites] Ann Oncol. 2009 May;20(5):842-9 [19153117.001]
  • [RetractionIn] Clin Cancer Res. 2014 Jun 15;20(12):3358 [24928947.001]
  • (PMID = 20670944.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES015704-04; United States / NCI NIH HHS / CA / P50CA58183; United States / NIEHS NIH HHS / ES / R01 ES015704; United States / NIEHS NIH HHS / ES / ES015704; United States / NCI NIH HHS / CA / P50 CA058183; United States / NCI NIH HHS / CA / R01 CA094118
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Retracted Publication; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Hormone Antagonists; 0 / Immunoglobulins, Intravenous; 67763-96-6 / Insulin-Like Growth Factor I; VE267FC2UB / figitumumab
  • [Other-IDs] NLM/ NIHMS226076; NLM/ PMC2952544
  •  go-up   go-down


15. Nakamura H, Kuirhara Y, Matsushita K, Sakai A, Yamaguchi T, Nakajima Y: Extrarenal multiorgan metastases of collecting duct carcinoma of the kidney: a case series. J Med Case Rep; 2008;2:304

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extrarenal multiorgan metastases of collecting duct carcinoma of the kidney: a case series.
  • INTRODUCTION: Collecting duct carcinoma is a rare type of renal cell carcinoma.
  • CASE PRESENTATION: We present two case reports of multiorgan metastases of collecting duct carcinoma that were autopsy confirmed.
  • Abdominal computed tomography showed enlargement of the right kidney.
  • These lesions were biopsied, resulting in a histological diagnosis of metastatic adenocarcinoma.
  • Transitional cell carcinoma was suspected, which proved to be misdiagnosed and chemotherapy was given accordingly.
  • Autopsy demonstrated the primary tumor to be collecting duct carcinoma, with metastases to lung, liver, spleen, bone marrow, right adrenal gland, and para-aortic lymph node.
  • Computed tomography done while the patient was alive detected lung, liver, and para-aortic lymph node metastases.
  • Antibiotic therapy improved his symptoms and laboratory indicators of inflammation.
  • One year later, he developed backache.
  • Computed tomography revealed a progressively enlarging right renal lesion, multiple liver masses, enlargement of the para-aortic lymph nodes, and multiple osteoblastic and osteoclastic lesions.
  • Chemotherapy was given without effect, and the patient died of cardiac failure 1 year later.
  • Autopsy revealed a primary tumor of collecting duct carcinoma with metastases to the liver, right adrenal gland, right upper ureter, bone marrow, para-aortic and mediastinal lymph nodes, and bone.
  • CONCLUSION: We present the radiological findings of lung, liver, lymph node, and bone metastases in two patients with collecting duct carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1986 Nov;10(11):1131-41 [3542784.001]
  • [Cites] Hum Pathol. 1990 Apr;21(4):449-56 [2318486.001]
  • [Cites] J Urol. 2003 Apr;169(4):1287-90 [12629344.001]
  • [Cites] AJR Am J Roentgenol. 2001 Mar;176(3):627-33 [11222193.001]
  • [Cites] Histopathology. 1991 Feb;18(2):115-22 [1707029.001]
  • [Cites] J Urol. 2000 Apr;163(4):1090-5; quiz 1295 [10737472.001]
  • [Cites] Eur J Radiol. 2006 Mar;57(3):453-60 [16266796.001]
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):54-67 [9503506.001]
  • [Cites] J Comput Assist Tomogr. 1996 May-Jun;20(3):399-403 [8626899.001]
  • [Cites] Arch Esp Urol. 2000 Sep;53(7):611-6 [11037654.001]
  • (PMID = 18798981.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2556681
  •  go-up   go-down


16. Lehmann J, Suttmann H, Albers P, Volkmer B, Gschwend JE, Fechner G, Spahn M, Heidenreich A, Odenthal A, Seif C, Nürnberg N, Wülfing C, Greb C, Kälble T, Grimm MO, Fieseler CF, Krege S, Retz M, Schulte-Baukloh H, Gerber M, Hack M, Kamradt J, Stöckle M: Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol; 2009 Jun;55(6):1293-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05).
  • BACKGROUND: Recent publications suggest a benefit from surgical removal of urothelial carcinoma metastases (UCM) for a subgroup of patients.
  • INTERVENTION: Resected metastatic sites were the following: retroperitoneal lymph nodes (56.8%), distant lymph nodes (11.3%), lung (18.2%), bone (4.5%), adrenal gland (2.3%), brain (2.3%), small intestine (2.3%), and skin (2.3%).
  • Systemic chemotherapy was administered in 35 of 44 patients (79.5%) before and/or after UCM surgery.
  • MEASUREMENTS: Overall, cancer-specific and progression-free survival from time of diagnosis and metastasectomy of UCM.
  • RESULTS AND LIMITATIONS: Median survival from initial diagnosis of UCM and subsequent resection was as follows: overall survival, 35 mo and 27 mo; cancer-specific survival, 38 mo and 34 mo; and progression-free survival, 19 mo and 15 mo.
  • Metastasectomy in patients with disseminated UCM remains investigational and should only be offered to those with limited disease as a combined-modality approach with systemic chemotherapy.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Carcinoma, Transitional Cell / surgery. Lymph Node Excision / methods. Urologic Neoplasms / pathology. Urologic Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cohort Studies. Disease-Free Survival. Female. Germany. Humans. Kaplan-Meier Estimate. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2009 Jun;55(6):1300-1 [19124189.001]
  • (PMID = 19058907.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


17. Chong JT, Mick A: Choroidal metastasis: case reports and review of the literature. Optometry; 2005 May;76(5):293-301
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Their diagnosis has become more common due to increased emphasis on comprehensive eye examinations for cancer patients and the improved life expectancy of patients with metastatic disease.
  • They are most prevalent in female patients with breast cancer and male patients with lung cancer.
  • METHODS: A thorough fundus examination, coupled with the use of A-scan and B-scan ultrasonography, will aid in their diagnosis.
  • There are many ways of treating these tumors, including radiation therapy, chemotherapy, and monitoring.
  • Case 1 involved a patient with lung cancer who manifested a large bullous exudative retinal detachment due to an underlying choroidal metastasis.
  • Case 2 dealt with treatment of a patient with metastatic transitional cell cancer who manifested a shallow exudative retinal detachment caused by a choroidal metastasis.
  • CONCLUSIONS: Due to progress of chemotherapeutic medications, the number of patients who manifest choroidal metastases will continue to increase.
  • It is essential for the practitioner to be able to recognize this disease process to prevent visual loss and institute referral for proper treatment for metastatic disease.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Choroid Neoplasms / secondary. Lung Neoplasms / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Disease Progression. Humans. Incidence. Magnetic Resonance Imaging. Male. Middle Aged. Retinal Detachment / diagnosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15884419.001).
  • [ISSN] 1529-1839
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Hara S, Ito K, Nagata H, Tachibana M, Murai M, Hata J: [Choriocarcinoma of the renal pelvis: a case report]. Hinyokika Kiyo; 2000 Feb;46(2):117-21
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The urinary cytology from the left renal pelvis indicated class IV, and the microscopic findings of a bladder biopsy demonstrated grade 1 transitional cell carcinoma.
  • The pathological diagnosis was high grade transitional cell carcinoma with choriocarcinomatous component.
  • After the operation, the serum human chorionic gonadotropin-beta (hCG-beta) level was slightly elevated, and the combination chemotherapy with methotrexate, vinblastine and cisplatin (MVC) was administered.
  • Although the serum hCG-beta level fell to 0.1 ng/ml, after two courses of MVC chemotherapy, bilateral pulmonary metastases appeared in the chest X-ray with increasing hCG-beta levels.
  • Salvage chemotherapy with cisplatin, etoposide and bleomycin (PEB) was performed.
  • After two courses of PEB chemotherapy, the serum hCG-beta level fell to within the normal range and all pulmonary metastases disappeared.
  • [MeSH-major] Carcinoma, Transitional Cell / therapy. Choriocarcinoma / therapy. Kidney Neoplasms / therapy. Neoplasms, Multiple Primary. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Kidney Pelvis. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10769802.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Number-of-references] 12
  •  go-up   go-down


19. Ito M, Okumura K, Nishio Y: [A case of human chorionic gonadotropin-producing bladder cancer]. Hinyokika Kiyo; 2001 Jan;47(1):47-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since histological examination showed grade 3 transitional cell carcinoma containing giant cells that were positive for beta-human chorionic gonadotropin (beta-HCG), we made a diagnosis of beta-HCG-producing bladder cancer.
  • Because of his advanced age and poor general condition, the patient underwent partial cystectomy alone without adjuvant chemotherapy.
  • One month later, a chest X-ray film revealed multiple lung metastases, and he developed paraplegia of the lower extremities suggesting spinal metastases.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Chorionic Gonadotropin, beta Subunit, Human / biosynthesis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Cystectomy. Fatal Outcome. Humans. Lung Neoplasms / secondary. Male. Spinal Cord Neoplasms / secondary

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11235222.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


20. Ma B, Seymour JF, Januszewicz H, Slavin MA: Cure of pulmonary Rhizomucor pusillus infection in a patient with hairy-cell leukemia: role of liposomal amphotericin B and GM-CSF. Leuk Lymphoma; 2001 Nov-Dec;42(6):1393-9
Hazardous Substances Data Bank. AMPHOTERICIN B .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cure of pulmonary Rhizomucor pusillus infection in a patient with hairy-cell leukemia: role of liposomal amphotericin B and GM-CSF.
  • A 77 year-old man had a background of chronic neutropenia due to hairy-cell leukemia, splenectomy, corticosteroid therapy and an obstructing left ureteric transitional-cell carcinoma.
  • Treatment was complicated by mild reversible deterioration of renal function.
  • There was a near complete radiological response to the therapy at 6 months and the patient remains well 20 months following diagnosis of R. pusillus and 13 months following cessation of treatment.
  • [MeSH-major] Amphotericin B / administration & dosage. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Leukemia, Hairy Cell / complications. Lung Diseases, Fungal / drug therapy. Mucormycosis / drug therapy. Rhizomucor
  • [MeSH-minor] Aged. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Liposomes. Male

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911424.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Liposomes; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7XU7A7DROE / Amphotericin B; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


21. Giannarini G, Kessler TM, Thoeny HC, Nguyen DP, Meissner C, Studer UE: Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution? Eur Urol; 2010 Oct;58(4):486-94
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The need for and intensity of follow-up to detect disease recurrence after radical cystectomy (RC) for transitional cell carcinoma (TCC) remains a matter for debate.
  • OBJECTIVE: To determine whether diagnosis of asymptomatic recurrence after RC by routine follow-up investigations confers a survival benefit versus symptomatic recurrence.
  • DESIGN, SETTING, AND PARTICIPANTS: Retrospective analysis of 479 patients with nonmetastatic bladder TCC receiving no neoadjuvant chemotherapy/radiation therapy and prospectively followed with a standardised protocol for a median 4.3 yr (range: 0.3-20.9) after RC at an academic tertiary referral centre.
  • The effects of age, nerve-sparing surgery, pathologic tumour stage, lymph node status, adjuvant chemotherapy, mode of recurrence diagnosis, and recurrence site on survival were assessed with multivariable Cox regression models.
  • Routine follow-up mostly detected lung metastases and urethral recurrences, while symptoms were predominantly the result of bone metastases and concomitant pelvic/distant recurrences.
  • Of 24 patients with urethral recurrences, 13 had carcinoma in situ (CIS).
  • Of these, 12 were successfully managed with urethra-sparing treatment, and 6 are still alive with no evidence of disease.
  • Most other recurrent long-term survivors had lung and extrapelvic lymph node metastases.
  • In multivariable analysis, mode of recurrence diagnosis and site of initial recurrence were the only independent predictors of CSS and OS.
  • Routine follow-up appears particularly effective in early detection of urethral CIS, which can be treated conservatively.
  • In addition, the predominance of lung and extrapelvic lymph node metastases in survivors may justify the use of routine cross-sectional imaging.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / surgery. Cystectomy. Ileum / transplantation. Neoplasm Recurrence, Local / diagnosis. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery. Urinary Reservoirs, Continent
  • [MeSH-minor] Aged. Early Detection of Cancer. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • [CommentIn] Eur Urol. 2010 Oct;58(4):495-7 [20609511.001]
  • (PMID = 20541311.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


22. Murakami T, Komiya A, Mikata K, Kaneko S, Ikeda I: Cardiac metastasis of renal pelvic cancer. Int J Urol; 2007 Mar;14(3):240-1
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seven months previously he had undergone a laparoscopic left nephroureterectomy for a left renal pelvic tumor and was given two cycles of adjuvant chemotherapy (methotrexate, epirubicin and cisplatin).
  • On computed tomography, multiple lung tumors, as well as the right atrial and ventricular mass, were seen.
  • On autopsy, a right atrial and ventricular metastasis of the initial transitional cell carcinoma was found.
  • The patient's cause of death was acute heart failure as a result of cardiac metastasis of his initial renal pelvic carcinoma.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Heart Neoplasms / secondary. Kidney Neoplasms / pathology. Kidney Pelvis
  • [MeSH-minor] Aged. Diagnosis, Differential. Echocardiography. Fatal Outcome. Humans. Laparoscopy. Male. Nephrectomy / methods. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17430263.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


23. Lehmann J, Suttmann H, Albers P, Volkmer B, Gschwend JE, Fechner G, Spahn M, Heidenreich A, Odenthal A, Seif C, Nürnberg N, Wülfing C, Greb C, Kälble T, Grimm MO, Fieseler CF, Krege S, Retz M, Schulte-Baukloh H, Gerber M, Hack M, Kamradt J, Stöckle M: [Complete resection of urothelial cancer metastases with curative intent]. Urologe A; 2009 Feb;48(2):143-50
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Recent publications suggest that a subgroup of patients can benefit from surgical removal of transitional cell carcinoma (TCC) metastases in addition to systemic chemotherapy.
  • RESULTS: The resected metastatic sites consisted of retroperitoneal lymph nodes (56.8%), distant lymph nodes (11.3%), lung (18.2%), bone (4.5%), adrenal gland (2.3%), brain (2.3%), small intestine (2.3%), and skin (2.3%).
  • The treatment sequence included systemic chemotherapy in 35/44 (79.5%) patients before and/or after surgery.
  • Median survival times from initial diagnosis of metastatic TCC and subsequent resection were as follows: overall survival, 35 and 27 months, respectively; cancer-specific survival, 38 and 34 months, respectively; and progression-free survival, 19 and 15 months, respectively.
  • Seventeen patients were still alive without progression at a median follow-up time of 8 months.
  • However, prospective data to identify patients most likely to benefit from this aggressive therapeutic approach are lacking.
  • Therefore, metastasectomy in patients with disseminated TCC remains investigational and should be offered only to those with limited disease as a combined-modality approach with systemic chemotherapy.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Carcinoma, Transitional Cell / surgery. Cystectomy / methods. Urinary Bladder Neoplasms / secondary. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Humans. Lymphatic Metastasis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2003 Jun;169(6):2113-7 [12771730.001]
  • [Cites] J Urol. 1994 Mar;151(3):598-600; discussion 600-1 [8308966.001]
  • [Cites] J Urol. 2001 Mar;165(3):811-4 [11176475.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2546-52 [10561321.001]
  • [Cites] J Urol. 2006 Jul;176(1):53-7; discussion 57 [16753366.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1361-7 [11870180.001]
  • [Cites] Eur Urol. 2007 Oct;52(4):1106-13 [17367917.001]
  • [Cites] Curr Opin Urol. 2004 Sep;14(5):287-93 [15300149.001]
  • [Cites] J Urol. 1993 Jul;150(1):65-9 [8510277.001]
  • [Cites] Eur Urol. 2002 Feb;41(2):105-12 [12074395.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):666-75 [11157016.001]
  • [Cites] J Urol. 2004 Jan;171(1):145-8 [14665863.001]
  • [Cites] J Clin Oncol. 1990 Jun;8(6):1050-5 [2189954.001]
  • [Cites] J Urol. 2002 Mar;167(3):1295-8 [11832716.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):483-8 [7509853.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2638-46 [11352955.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3068-77 [11001674.001]
  • [Cites] Eur Urol. 2009 Jun;55(6):1293-9 [19058907.001]
  • [Cites] Urology. 2001 Jan;57(1):55-9 [11164143.001]
  • [Cites] J Urol. 1988 Mar;139(3):461-9 [3343727.001]
  • [Cites] Urology. 1982 Oct;20(4):390-2 [7147508.001]
  • (PMID = 19142626.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


24. Abe T, Konari S, Ogata M, Komatsu S, Satoh T: [A case of CEA-producing renal pelvic and ureteral cancer]. Hinyokika Kiyo; 2003 Feb;49(2):75-9
Genetic Alliance. consumer health - Kidney cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CA19-9 was also positive both in the tumor cells and normal epithelium of the renal tubules.
  • Postoperatively, multiple lung metastases developed despite chemotherapy and the patient died 4 months after surgery.
  • CEA had transiently decreased postoperatively, but then increased with lung metastases, apparently related to the state of cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Carcinoma, Transitional Cell / diagnosis. Kidney Pelvis / immunology. Ureteral Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12696186.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen
  • [Number-of-references] 17
  •  go-up   go-down


25. Bang SM, Park SR, Park SH, Cho EK, Yoon SS, Shin DB, Lee JH, Park S, Kim BK, Kim NK: Clinical features of Waldenstrom macroglobulinemia in Korea. Korean J Intern Med; 2004 Sep;19(3):137-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • B symptoms and hyperviscosity requiring plasmapheresis existed in 5 and 4 patients, respectively, at the time of diagnosis.
  • Sites of extranodal involvement were bone (3) and lung (1) in 3 patients.
  • One patient had transitional cell carcinoma concomitantly, and one patient developed small cell lung cancer.
  • Of the 11 patients receiving chemotherapy (7-chlorambucil, 2-melphalan, 1-cyclophosphamide, 1-CHOP), 4 patients showed the objective responses including 2 complete remissions, but they all ultimately relapsed.
  • The response rate of second-line therapy was 14% (1/7).
  • [MeSH-major] Waldenstrom Macroglobulinemia / diagnosis

  • Genetic Alliance. consumer health - Waldenstrom macroglobulinemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15481603.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Immunoglobulin M
  • [Other-IDs] NLM/ PMC4531566
  •  go-up   go-down






Advertisement